WOODBRIDGE, ON, Sept. 6, 2012 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on cardiovascular
disease and overall health, is pleased to announce that Dr. George
Jackowski, Chief Scientific Officer will be presenting at the Rodman &
Renshaw 14th Annual Healthcare Conference. The conference will be held at the
Waldorf Astoria in New York, NY from September 9-11, 2012.
Dr. Jackowski will provide a corporate update and discuss the recent
data showing the superior efficacy of VASCAZENTM's unique formulation that was presented at the European Society of
Cardiology Congress 2012, as well as exciting future prospects for VASCAZENTM beyond the Medical Food area. This presentation will take place on
Monday September 10, 2012 at 4:55 pm EST in the Starlight South room.
Also joining him is Mr. Eugene Bortoluzzi, Chief Executive Officer and
Chief Financial Officer and Ms. Rachelle MacSweeney, President and
Chief Operating Officer. They will all be available to participate in
one-on-one meetings with investors who are registered to attend the
conference.
About Pivotal Therapeutics Inc.
With offices in Toronto, Canada and Boca Raton, Florida, Pivotal
Therapeutics is a publicly traded (OTCQX: PVTTF); (CNSX: PVO) specialty
pharmaceutical company with a focus on cardiovascular disease and
overall health. Pivotal Therapeutics' lead product VASCAZENTM is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications.
VASCAZENTM is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected
by a series of both issued and pending US and foreign patents and
commercialized as a prescription only Medical Food in the U.S. This
unique formulation will provide the cornerstone upon which a family of
cutting edge combination products, with efficacy across a broad
spectrum of cardiac care, will be commercialized.
OMAZENTM is a >90% pure, proprietary EPA:DHA fatty acid formulation
commercialized for sale and distribution in Canada for the maintenance
of good health through elevating Omega-3 fatty acid levels. The unique
formulation and dosage will be available to patients and consumers who
realize the health benefits of Omega-3 supplementation with a quality
product.
Disclosure Notice
The information contained in this document is as of September 6, 2012.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual results
to differ materially from those projected in such forward-looking
statements. These statements can be identified by the use of words such
as "will", "anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause actual
results to differ materially from those in forward looking statements
include the following: Pivotal's inability to obtain additional
financing on acceptable terms; growth in costs and expenses; inability
to compete with others who provide comparable products; risk that the
Company's products will not gain widespread market acceptance; risks
relating to the Company's ability to maintain its CSNX listing.
Forward-looking statements speak only as of the date made and are not
guarantees of future performance. The Company undertakes no obligation
to publicly update or revise any forward-looking statements contained
in this document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.
SOURCE Pivotal Therapeutics Inc.